HLA-E
-
Official Full Name
major histocompatibility complex, class I, E -
Overview
HLA-E belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. HLA-E binds a restricted subset of peptides derived from the leader peptides of other class I molecules. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domains, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exons 6 and 7 encode the cytoplasmic tail. -
Synonyms
HLA-E;major histocompatibility complex, class I, E;HLA class I histocompatibility antigen, alpha chain E;MHC HLA-E alpha-1;lymphocyte antigen;MHC HLA-E alpha-2.1;MHC class I antigen E;HLA class I histocompatibility antigen, E alpha chain;MHC;QA1;EA1.2;EA2.1;HLA-6.2;DKFZp686P19218
Recombinant Proteins
- Human
- E.coli
- HEK293
- Insect Cells
- Mammalian Cells
- In Vitro Cell Free System
- His
- Non
- Avi
- Fc
- Myc
- Flag
- GST
- SUMO
| Cat.# | Product name | Source (Host) | Species | Tag | Protein Length | Price |
|---|---|---|---|---|---|---|
| HLA-E-3399H | Recombinant Human HLA-E protein, His-tagged | E.coli | Human | His | 23-303 aa | |
| HLA-E-1746H | Recombinant Human HLA-E protein, His-tagged | E.coli | Human | His | Gly22~Leu358 |
|
| HLA-E-800HCL | Recombinant Human HLA-E cell lysate | Human | Non |
|
||
| HLA-E-038H | Recombinant Human HLA-E protein, His-Avi-tagged | HEK293 | Human | Avi&His | It contains Gly25-Ile305(HLA-E),Ile21-Met119(B2M) and VMAPRTLVL peptide. |
|
| HLA-E-039H | Recombinant Human HLA-E protein, His-Avi-tagged, Biotinylated | HEK293 | Human | Avi&His | It contains Gly25-Ile305(HLA-E),Ile21-Met119(B2M) and VMAPRTLVL peptide. |
|
| HLA-E-040HP | Recombinant Human HLA-E complex Protein (tetramer), His-Avi-tagged, PE-Labeled | HEK293 | Human | Avi&His | Gly25-Ile305(HLA-E*01:03),Ile21-Met119(B2M) and VMAPRTLVL peptide |
|
| HLA-E-1076H | Recombinant Human HLA-E Protein, His (Fc)-Avi-tagged | HEK293 | Human | Avi&Fc&His |
|
|
| HLA-E-1076H-B | Recombinant Human HLA-E Protein Pre-coupled Magnetic Beads | HEK293 | Human |
|
||
| HLA-E-2276H | Recombinant Human HLA-E protein, His&Myc-tagged | Insect Cells | Human | His&Myc | 22-305aa |
|
| HLA-E-268HFL | Recombinant Full Length Human HLA-E Protein, C-Flag-tagged | Mammalian Cells | Human | Flag | Full L. |
|
| HLA-E-3602HF | Recombinant Full Length Human HLA-E Protein, GST-tagged | In Vitro Cell Free System | Human | GST | Full L. 358 amino acids |
|
| HLA-E-3872H | Recombinant Human HLA-E protein, His-SUMO-tagged | E.coli | Human | His&SUMO | 22-305aa |
|
Involved Pathway
HLA-E involved in several pathways and played different roles in them. We selected most pathways HLA-E participated on our site, such as Endocytosis,Phagosome,Cell adhesion molecules (CAMs), which may be useful for your reference. Also, other proteins which involved in the same pathway with HLA-E were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|---|
| Viral myocarditis | ACTG1,CD86,H2-AB1,RAC3,RAC2,H2-Q10,CASP9,ITGB2,HLA-C,FYN |
| Type I diabetes mellitus | HLA-DRB3,IL12B,TNF,GAD1,HLA-F,Fasl,HLA-DOA,H2-AA,HLA-DRB4,PTPRN |
| Allograft rejection | IL5,CD80,HLA-DPB1,HLA-DPA1,Il2,HLA-B,TNF,CD40,HLA-DMB,HLA-DQA2 |
| Cell adhesion molecules (CAMs) | HLA-DQA1,NLGN3A,ITGB1B.2,CLDNE,NRXN2,PDCD1,ITGA8,SELL,CNTN1A,TIGIT |
| Epstein-Barr virus infection | ENTPD8,RBPJ,MAP2K7,NFKBIB,DDX58,IKBKG,MAP2K3,MAPK13,MAP2K4,PSMD6 |
| Antigen processing and presentation | HLA-DRB5,PSME1,KLRC2,KIR2DL1,HLA-DMB,CTSB,HLA-DRB3,HSPA2,CALR,HSPA1B |
| Phagosome | ITGAV,CLEC7A,LAMP1,STX7,THBS3,TUBB6,DYNC1LI1,LAMP2,CD209,DYNC1I1 |
| Graft-versus-host disease | HLA-C,IL1A,HLA-DRB5,Il2,CD86,HLA-DRB4,HLA-DRA,Fasl,HLA-DQA1,H2-AB1 |
| Herpes simplex infection | TYK2,TBPL1,IFNGR2,CDC34,CSNK2A2A,HLA-F,H2-Q10,TBP,SRSF5,NXF2 |
Protein Function
HLA-E has several biochemical functions, for example, MHC class I protein binding,beta-2-microglobulin binding,natural killer cell lectin-like receptor binding. Some of the functions are cooperated with other proteins, some of the functions could acted by HLA-E itself. We selected most functions HLA-E had, and list some proteins which have the same functions with HLA-E. You can find most of the proteins on our site.
| Function | Related Protein |
|---|---|
| natural killer cell lectin-like receptor binding | Raet1a,ULBP2,CLEC2H,RAET1E,ULBP1,RAET1G,SAMD3,MICA,CLEC2G,ULBP3 |
| peptide antigen binding | TRGV3,HLA-DRB4,MHC1UXA2,MHC1UJA,MR1,H2-AA,H2-AB1,TAPBP,HLA-G,MHC1ZKA |
| beta-2-microglobulin binding | CD1A,CD1C,CD1D,FCGRT,CD1D2,CD1B,CD1d1,HLA-A,H2-Q10,CD1E |
| receptor binding | Ar,CAV1,NTF3,CCL15,CXCL1,RIPK2,PAOX,IZUMO1,POU2F1,FIS1 |
| MHC class I protein binding | TUBB,CD244,CD8A,TAP1,Pilrb1,TUBB4B,LILRB1,BCAP31,LILRB2,PILRB2 |
Interacting Protein
HLA-E has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with HLA-E here. Most of them are supplied by our site. Hope this information will be useful for your research of HLA-E.
YPMT1.25Ac;TRAPPC2;fusA;lldD1;q5ni35_fratt;q7chg5_yerpe;proW;q7ckk6_yerpe;deoB;ptsG;y2173_bacan;q81wx2_bacan;dacF;q81z87_bacan;q8cl08_yerpe;sfcA2;leuB;PPP1R16A
Resources
Research Area
Related Services
Related Products
References
- Cheung, PFY; Yip, CW; et al. Granulin-Epithelin Precursor Renders Hepatocellular Carcinoma Cells Resistant to Natural Killer Cytotoxicity. CANCER IMMUNOLOGY RESEARCH 2:1209-1219(2014).
- Ravindranath, MH; Terasaki, PI; et al. Suppression of blastogenesis and proliferation of activated CD4(+) T cells: intravenous immunoglobulin (IVIg) versus novel anti-human leucocyte antigen (HLA)-E monoclonal antibodies mimicking HLA-I reactivity of IVIg. CLINICAL AND EXPERIMENTAL IMMUNOLOGY 178:154-177(2014).
